InsiderTrades

Form 4 for ELUT ELUTIA INC.

Accepted 2023-09-21 00:00:00 ET · period of report 2023-09-21 · accession 0001415889-23-013473 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2023-09-21 2023-09-21 ELUT Ferguson Matthew CFO A - Grant — +70.1K 120.5K +139% —
D 2023-09-21 2023-09-21 ELUT Ferguson Matthew CFO A - Grant — +105.1K 105.1K New —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Class A Common Stock 2023-09-21 A A 70,053 — 120,519 D — — (F1) The reported securities are included within the 70,053 Units purchased by the reporting person for $1.4275 per Unit. Each Unit consists of one share of Class A Common Stock and one warrant to purchase one and one-half shares of Class A Common Stock. (F2) Includes 901 shares of Class A Common Stock acquired under the Company's 2020 Employee Stock Purchase Plan.
2 Derivative Warrants (rights to buy) 2023-09-21 A A 105,080 — 105,080 D $1.43 · 2023-09-21 to — 105,080 Class A Common Stock (F1) The reported securities are included within the 70,053 Units purchased by the reporting person for $1.4275 per Unit. Each Unit consists of one share of Class A Common Stock and one warrant to purchase one and one-half shares of Class A Common Stock. (F3) The warrant expires upon the earlier of (a) 30 trading days after the clearance by the U.S. Food & Drug Administration of the issuer's CanGarooRM antibiotic-eluting biologic envelope or (b) September 21, 2028.